# A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

> **NCT05889988** · — · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 36 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05889988
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889988, "A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05889988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*